GlassScriptPhysician profile
Brooke Carroll
NPI 1508389180
$2,081.56
in general payments reported to CMS, 2019-2025
22 companies · $14.89 in 2025
The $14.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.55 · 2022: $506 · 2023: $879 · 2024: $670 · 2025: $14.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.85 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $405.91 | 2022-2024 | |
| Glaxosmithkline, LLC. | $179.52 | 2022-2024 | Trelegy Ellipta |
| Pfizer INC. | $155.58 | 2022-2024 | |
| Lilly USA, LLC | $134.36 | 2021-2023 | Mounjaro, Jardiance |
| Amgen INC. | $127.92 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $86.84 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $71.77 | 2022-2023 | |
| Dexcom, INC. | $70.05 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $67.02 | 2022-2024 | Airsupra |
| Astellas Pharma US INC | $61.57 | 2022-2024 | Veozah |
| Abbott Laboratories | $46.01 | 2024 | Jot Dx, Freestyle Libre |
| Inogen, INC. | $33.31 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Purdue Pharma L.P. | $31.03 | 2024 | Nalmefene Hydrochloride |
| Regeneron Healthcare Solutions, INC. | $27.90 | 2023 | Evkeeza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.37 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.52 | 2024 | Stiolto Respimat |
| Axonics, INC. | $19.07 | 2023 | Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.35 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $16.30 | 2022 | |
| Shield Therapeutics INC | $14.18 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.